News

An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.

These findings suggest that those with atopic dermatitis exacerbations may need to limit their oral corticosteroid duration for the purposes of limiting AEs.

Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.

Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.

RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.

The XTEND-Kids phase 3 trial shows efanesoctocog alfa’s safety and efficacy in children with severe hemophilia A, reducing bleeds with once-weekly dosing.

In this Q&A interview, Stein Gold discusses new phase 3 findings regarding ruxolitinib cream 1.5% for patients 2 to 11 years old with atopic dermatitis.

The novel potassium-competitive acid blocker now boasts 3 FDA approvals across erosive and non-erosive GERD, expanding the treatment armamentarium for patients and clinicians.

Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.

Vonoprazan (Voquezna), the first major innovation in GERD treatment in more than 30 years, is now FDA-approved for both erosive and non-erosive GERD.

Adalimumab-adbm is now available at a 92% discount from the reference drug list price through GoodRx.

OTX-TKI remained generally well-tolerated in patients with moderately severe to severe NPDR across 48 weeks of the Phase 1 trial.

Announced on July 18, 2024, the FDA approval for heartburn relief associated with non-erosive GERD is based on the phase 3 PHALCON-NERD-301 trial.

Katherine Talcott, MD describes a posthoc analysis of the GATHER trials showing how imaging biomarkers of photoreceptor structure predict GA growth.

Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.

The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.

These data suggest that risk of developing psoriatic arthritis among patients with different variants of psoriasis vary based on race and sex as well.

A new study showed the efficiency and speed of a new AI model for a heart scan.

The cross-sectional analysis found Medicaid nonexpansion status, fibrosis, and sobriety restrictions negatively impacted annual rates of DAA prescription fills.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.

Health literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.

In this interview, Rosmarin discussed the results of a new post-hoc analysis of the TRuE-V1 and TRuE-V2 studies on treating younger vitiligo patients with ruxolitinib cream.

A study with real-world data showed certolizumab pegol was effective in treating psoriasis a year later, with a probability of 1-year persistence at approximately 85%.

Findings highlight an increased risk of diabetes, MASLD, and cardiovascular disease in patients with PCOS, with risk varying by PCOS phenotype.

Phase 2a results demonstrated the efficacy and safety of orally administered CU06-1004 and may warrant further clinical studies in DME.

SGLT2 inhibitors may provide a favorable impact on the risk of sight-threatening diabetic retinal complications compared with other glucose-lowering therapies.